These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32559581)

  • 1. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
    Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
    Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
    Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
    Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).
    Romero FA; Murray J; Lai KW; Tsui V; Albrecht BK; An L; Beresini MH; de Leon Boenig G; Bronner SM; Chan EW; Chen KX; Chen Z; Choo EF; Clagg K; Clark K; Crawford TD; Cyr P; de Almeida Nagata D; Gascoigne KE; Grogan JL; Hatzivassiliou G; Huang W; Hunsaker TL; Kaufman S; Koenig SG; Li R; Li Y; Liang X; Liao J; Liu W; Ly J; Maher J; Masui C; Merchant M; Ran Y; Taylor AM; Wai J; Wang F; Wei X; Yu D; Zhu BY; Zhu X; Magnuson S
    J Med Chem; 2017 Nov; 60(22):9162-9183. PubMed ID: 28892380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
    Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
    Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
    Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
    Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
    Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insight into the recognition of acetylated histone H3K56ac mediated by the bromodomain of CREB-binding protein.
    Xu L; Cheng A; Huang M; Zhang J; Jiang Y; Wang C; Li F; Bao H; Gao J; Wang N; Liu J; Wu J; Wong CCL; Ruan K
    FEBS J; 2017 Oct; 284(20):3422-3436. PubMed ID: 28815970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
    Xing J; Zhang R; Jiang X; Hu T; Wang X; Qiao G; Wang J; Yang F; Luo X; Chen K; Shen J; Luo C; Jiang H; Zheng M
    Eur J Med Chem; 2019 Feb; 163():281-294. PubMed ID: 30529546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.
    Crawford TD; Romero FA; Lai KW; Tsui V; Taylor AM; de Leon Boenig G; Noland CL; Murray J; Ly J; Choo EF; Hunsaker TL; Chan EW; Merchant M; Kharbanda S; Gascoigne KE; Kaufman S; Beresini MH; Liao J; Liu W; Chen KX; Chen Z; Conery AR; Côté A; Jayaram H; Jiang Y; Kiefer JR; Kleinheinz T; Li Y; Maher J; Pardo E; Poy F; Spillane KL; Wang F; Wang J; Wei X; Xu Z; Xu Z; Yen I; Zawadzke L; Zhu X; Bellon S; Cummings R; Cochran AG; Albrecht BK; Magnuson S
    J Med Chem; 2016 Dec; 59(23):10549-10563. PubMed ID: 27682507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
    Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
    Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
    Chen Z; Zhang H; Liu S; Xie Y; Jiang H; Lu W; Xu H; Yue L; Zhang Y; Ding H; Zheng M; Yu K; Chen K; Jiang H; Luo C
    Medchemcomm; 2017 Jun; 8(6):1322-1331. PubMed ID: 30108844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.
    Xu H; Luo G; Wu T; Hu J; Wang C; Wu X; Zhang Y; Xu Y; Xiang Q
    Biochem Biophys Res Commun; 2022 Oct; 623():17-22. PubMed ID: 35868068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
    Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
    Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Dimethylisoxazole-Attached Imidazo[1,2-
    Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
    J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association.
    Sachchidanand ; Resnick-Silverman L; Yan S; Mutjaba S; Liu WJ; Zeng L; Manfredi JJ; Zhou MM
    Chem Biol; 2006 Jan; 13(1):81-90. PubMed ID: 16426974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.